(Adds background in paragraphs 3, results in paragraph 4)
Jan 23 (Reuters) - Swedish medical technology group
Vitrolife VITR.ST said on Tuesday it will record a non-cash
impairment charge of 4.3 billion Swedish crowns ($409.44
million) in the fourth quarter, relating to its acquisition of
Igenomix.
The impairment charge represents 31% of the accounted
goodwill and intangible assets tied to the deal.
Vitrolife had bought reproductive genetic testing services
provider Igenomix in a deal worth 1.25 billion euros ($1.35
billion) in 2021.
Vitrolife's preliminary fourth-quarter sales rose 5.7% to
904 million Swedish crowns, while its earnings before interest,
tax, depreciation and amortization (EBITDA) increased more than
7% to 294 million Swedish crowns.
($1 = 10.5021 Swedish crowns)
($1 = 0.9228 euros)
(Reporting by Utkarsh Shetti in Bengaluru; Editing by Shilpi
Majumdar)
((UtkarshUmesh.Shetti@thomsonreuters.com;))